Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056324 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9986282 | 0.78 | ALDH1A1 (0.54) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL29862290 | 0.74 | PLA2G2A (0.59) | KMT2A | |
| SCHEMBL8758346 | 0.74 | ALDH1A1 (0.82) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5022814 | 0.74 | PTGER4 (0.43) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL9755646 | 0.69 | GPR3 (0.52) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14584015 | 0.68 | ALDH1A1 (0.54) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL21298409 | 0.67 | KDM4E (0.55) | ALDH1A1MEN1KMT2ALMNAMAPK1 | |
| SCHEMBL11454471 | 0.67 | CYP19A1 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL15824333 | 0.67 | KMT2A (0.45) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | ALDH1A1 2661/4885HTT 4814/4885MEN1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.